Table 1. Demographics and Baseline Characteristics (Treated Analysis Set).
| Immediate SwitchEFV/FTC/TDF | Delayed Switch (Continue ABC/3TC + EFV for 12 Weeks) | |
|---|---|---|
| Number of Subjects | 79 | 78 |
| Median age in yrs (IQR) | 42 (36, 48) | 44 (40, 50) |
| Race | ||
| White | 45 (57.0%) | 48 (61.5%) |
| Black | 29 (36.7%) | 27 (34.6%) |
| Asian | 2 (2.5%) | 0 |
| Other | 3 (3.8%) | 3 (3.9%) |
| Gender | ||
| Male | 61 (77.2%) | 64 (82.1%) |
| HIV RNA | ||
| < 50 copies/mL | 76/79 (96.2%) | 71/77 (92.2%) |
| < 400 copies/mL | 79/79 (100%) | 77/77 (100%) |
| Median CD4 (cells/microl) (IQR) | 459 (377, 604) | 450 (371, 584) |
| Median BMI (kg/m2) (IQR) | 25.7 (23.5, 29.3) | 25.8 (23.7, 28.0) |
| Median Fasting TC (mmol/L) ( IQR) | 6.62 (5.97, 7.26) | 6.19 (5.80, 6.78) |
| Number of Subjects on Prior Lipid Modifying Agents | 9 (11.4%) | 13 (16.7%) |